オクラホマにおける膀胱癌の臨床試験
オクラホマ内の拠点で、膀胱癌に関する12件の研究が参加者を募集しています。
オクラホマ内の都市
公式研究テキスト（英語）
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07000084Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06770582Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07061964Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Oklahoma - Health Sciences Center, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT05614739Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07097142A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/22更新 · NCT04879329A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/29更新 · NCT07327489SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。